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Introduction  
Type 2 Diabetes (T2D) most often occurs not as a single impair-
ment or risk factor, but as co-morbid with cardiovascular disease 
(CVD) and macrovascular complications [1-3]. Consequently pa-
tients diagnosed with T2D maybe required to manage medicines 
for hyperglycemia, hypertension and hyperlipidaemia [4]. Fur-
thermore, clinical trials such as the United Kingdom Prospective 
Diabetes Study [5], Steno-2 Study [6] and Collaborative Atorvas-
tatin Diabetes Study [7] advocate the intensification of  medicines 
to improve long-term outcomes for patients. In addition to the 
management of  multiple medicines, people with co-morbid T2D 
and CVD are often required to undertake lifestyle changes and 
perform a range of  self-care activities including self-monitoring 
of  blood pressure and blood glucose. The self-management of  
co-morbid T2D can be increasingly complex for patients.
Multiple barriers to medication adherence (the extent to which a 
patient takes their medicines as prescribed) in T2D have identi-
fied, including the cost of  medicines [8], social barriers [9], and 
beliefs about illness and treatment [10]. In addition, the presence 
of  co-morbidities and the prescription of  multiple medicines 
may have a negative impact on the way people self-manage [11]. 
Studies have shown that patients prescribed more medicines (i.e. 
multiple daily doses) have lower rate of  medication adherence 
[12, 13]. Evidence suggests that increasing numbers of  medicines 
leads to patient dissatisfaction and non-adherence [14].
A study of  multiple medicine adherence in people taking multiple 
medicines for comorbid T2D found that when large numbers of  
medicines were prescribed, medicines for hyperlipidaemia were 
Abstract
Background: Type 2 diabetes is associated with cardiovascular disease, and patients with both conditions are prescribed 
complex medication regimens. 
Aim: The aim was to develop a reliable and valid measure of  attitudes associated with the prescription and management of  
multiple medicines in patients with Type 2 diabetes and cardiovascular disease. 
Methods: Principal component analysis (PCA) and Cronbach alpha assessed the reliability of  the Attitudes about Complex 
Therapy Scale (ACTS). Examinations of  relationships with related measures inform concurrent validity. Questionnaires 
were sent to a cross-sectional sample of  480 people prescribed multiple medicines for co-morbid Type 2 diabetes. 
Results: Cronbach alpha was 0.76, indicating the scale had good internal reliability. PCA rotated a four factor model ac-
counting for 37% of  the variance. Four subscales identified; 1. Concerns about multiple medicines and increasing numbers 
of  medicines; 2.Anxiety over missed medicines; 3. Desires to substitute medicines and reduce the number of  medicines 
prescribed and; 4. Perceptions related to organising and managing complex therapy. The ACTS showed significant relation-
ships with measures of  anxiety, depression, general beliefs about medicines and self-efficacy. Also, the ACTS significantly 
correlated with adherence to medicines, showing good predictive validity. 
Conclusion: The ACTS was designed to assess negative attitudes towards complex therapy and multiple medication man-
agement. This tool could aid prescribing decisions and may identify people who are intentionally non-adherent to all or 
some of  their medicines.
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less likely to be taken (compared with medicines for hypertension 
and hypoglycaemia) [14]. Qualitative research has also found that 
CVD medicines are often undervalued by people with co-morbid 
T2D [15]. Patients explaining why low priority was given to CVD 
said they believed that CVD should be managed through lifestyle 
changes (not medicines) while T2D was perceived a severe condi-
tion requiring pharmacological management. Other studies have 
shown that patients with comorbid T2D tend prioritize their dia-
betes, and will adjusting their regimen to match their beliefs[16, 
17]. Elliott et al. suggested that variable use of  medicines, i.e. us-
ing some medicines more than others, is related to patients’ per-
sonal prioritisation of  medicines [18], while other studies have 
shown that multiple medicine regimens are associated with fear, 
uncertainty and lower control [19]. Also, patients fear chemical 
interactions and view medicines as a ‘last resort’, suggesting that 
people prescribed multiple medicines hold perceptions which re-
flect their personal self-management difficulties.
The beliefs people managing multiple medicines for T2D and 
CVD hold are not typically represented in measures of  illness 
perceptions, treatment perceptions or self-management behav-
iours. Questionnaires such as the illness perception questionnaire 
[20] and the beliefs about medicines questionnaire (BMQ) [21]
typically measure the perceptions of  people with single illnesses 
receiving single treatments. Therefore, perceptions specifically re-
lated to the decisions faced by people managing multiple chronic 
conditions, such as the prioritisation of  medicines, variable use of  
medicines and fears of  chemical interactions are not yet captured 
in clinical or research measures. The development of  a tool to 
measure perceptions relating to multiple medicines would help 
to identify the behavioural outcomes of  negative perceptions to-
wards multiple medicines and may also be of  use to clinicians 
wishing to identify people who are experiencing difficulties in 
medicines management.
Aim
The aim of  this research was to develop, validate and reliability 
test a new measure of  patient perceptions of  multiple medicines 
and difficulties in T2D and CVD. The attitudes about complex 
therapies scale (ACTS) was developed to address this aim.
Method
Ethics approval was granted from a Research Ethics Committee 
(reference number 07/Q1410/280).
Participants
Eligible participants were community dwelling adults (aged >18 
years) managing multiple medicines for co-morbid T2D and 
CVD that is, prescribed one or more oral hypoglycaemic agents 
for the treatment of  T2D; one or more anti-hypertensive drugs, 
and a statin for the treatment of  hyperlipidaemia (see Table 1). 
The details of  potential participants meeting the inclusion criteria 
were extracted from the secondary care diabetes database. Eligible 
participants had attended a secondary care diabetes clinic within 
12 months of  recruitment, to ensure that invitations were sent 
only to those who had recent healthcare services contact, and a 
medication review. For ethical reasons data could not be collected 
on non-participants.
Procedure
Participants were sampled for a secondary care diabetes database 
which incorporated prescribing information from secondary and 
primary care; this enhanced the reliability of  the prescribing data 
used in this research. Eligible patients were sent a battery of  ques-
tionnaires, an information sheet and letter of  invitation plus free 
post return envelope. Participation was anonymous. Two remind-
ers were sent to increase the response rate, the first two weeks 
after the initial mailing and the second followed two weeks after 
the first reminder. Informed signed consent was obtained from 
all participants.
Measures
The ACTS was developed from themes generated by 19 qualita-
tive interviews with people managing multiple medicines for T2D 
and CVD. Sections of  speech were taken from the verbatim inter-
view transcripts, interpreted and converted into attitudes (a judge-
ment about or preference towards an object, which is assumed to 
be driven by an underlying belief) and used as an item statement 
Table 1. Number and percentage of  participants prescribed each medicine.
Name of  medication Number of  patients
prescribed medication (%)
Metformin 388 (80.33)
Glitazones 74 (15.42)
Sulphonylureas 0 (0)
ACE Inhibitors 324 (67.5)
Calcium channel blockers 211 (43.96)
Angiotensin 2 receptor antagonists 128 (26.67)
Diuretics 126 (26.25)
Alpha blockers 49 (10.21)
Beta Blockers 0 (0)
Statins 480 (100)
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for the ACTS. The interviews generated the following themes: 
Desires to avoid additional medicines; variable use of  prescribed 
medicines; lifestyle modification vs. medicine use; chemicals vs. 
natural medicines; routine schedules and management; medica-
tion confusion and medication anxiety and emotions [15]. Thirty-
four items were extracted from patients statements (see Table 2), 
where possible the terminology and statement of  the person in-
terviewed was retained to generate scale times.
Where appropriate, items were reversed to prevent response bias. 
This was not always appropriate as sometimes positive wording 
detracted from its meaning, for example, “I don’t ask the phar-
macist to give me all the items on my prescription – I just don’t 
need them all” could have been changed to “I ask the pharmacist 
to give me all the items on my prescription as they are all impor-
tant” however this conveys a different type of  attitude, behaviour 
and meaning.  Only seven statements where the items were easily 
converted in to positive statements without losing meaning were 
selected. 
Each item had a five point Likert scale response format, ranging 
from strongly disagree (valued at 1) through to a neutral response 
(valued at 3) through to strongly agree (valued at 5). Respondents 
indicated the degree of  agreement with ACTS statements. The 
summation of  the scores given to each item used indicates the 
level of  negative attitudes towards multiple medicines. 
The ACTS and five criterion measures formed a questionnaire 
battery which was sent to each eligible participant. The first two 
criterion measures were the general harm and general overuse 
scale of  the BMQ [21]. Each BMQ general subscale contained 
four items, each measured on a five point Likert scale (score on 
each general subscale ranged between four and twenty). The third 
and fourth criterion measures were the depression and anxiety 
subscales of  the Hospital Anxiety and Depression Scale (HADS)
[22]. The HADS contains fourteen items and is a standard screen-
ing tool for depression (seven items) and anxiety (seven items) in 
healthcare setting. Each item is measured on a four point Likert 
scale; scores on the individual subscales range between zero and 
twenty-eight. The fifth criterion measure was the Diabetes Mel-
litus Self-efficacy (DMSE) scale [23]. The DMSE scale measures 
self-efficacy (motivation and perceived ability to perform a task) 
for tasks related to diabetes self-management. The scale consists 
of  eight items on diet, exercise and medication management self-
efficacy. Each item is measured on a ten point Likert scale; scores 
range between zero and eighty. The final measure used was the 
Morisky adherence scale [24]. This scale was used to explore the 
basic predictive validity of  the ACTS tool.
Analysis
Principal component analysis (PCA) identified items that achieve 
higher order correlations that cluster theoretically and statistically 
to form factors (missing values were excluded pairwise). Theo-
Table 2. Items grouped according to the four factor rotation and factor loadings.
Factor 1. Concerns about multiple medicines and increasing numbers of  medicines
The chemical in my medicines may be damaging my body .71
I’m scared the chemical in my medicines will interact with each other .71
I don’t know how my medicines work - it confuses me .7
I’m scared of  more medicines being added in the future .6
I feel like more and more medicines are being added to my treatment plan .57
I think some of  my medicines should be taken away .52
There is a particular medicines that I dislike above all the others I am taking .52
Factor 2. Anxiety over missed medicines
Being put in a situation where I can’t take my medicines worries me .81
I become anxious if  I miss my medication .76
I feel guilty if  I miss a dose or two .75
Factor 3. Desire to substitute medicines and reduce the number of  medicines prescribed
I plan to do more exercise to reduce the number of  medicines I am taking .77
I plan to improve my diet in order to reduce the number of  medicines I am taking .71
It may be possible for me to change my lifestyle and get rid of  some of  my medicines .7
I would rather change something about my lifestyle than take extra medicines .58
I plan to reduce the number of  medicines I am taking .55
In the future I would like to reduce the number of  medicines I am taking .45
I take most of  my medicines regularly, but not all of  them .33
Factor 4. Organising and managing complex therapy
I take my medicines without thinking about it too much - I don’t have a strategy or a plan .68
I’m not bothered by the number of  medicines I’ve been prescribed I just take them REVERSE .57
My medicines work because they are linked together and help each other out REVERSE .49
I plan to take herbal medicines in the future .44
I’m  happy to be prescribed more medicines .36
Rebecca J Stack, et al., (2015) The Attitudes about Complex Therapy Scale (ACTS) in Type 2 Diabetes and Cardiovascular Disease: Development, Validity and Reliability. 
Int J Diabetol Vasc Dis Res, 3(9) 130-136 133
www.scidoc.org/ijdvr.php
retically, the ACTS items were likely to be correlated; therefore, 
an oblique direct oblimin rotation was undertaken. Concurrent 
validity assessed the relationship between the ACTS and tools 
which measure similar constructs or criterion measures. Con-
current validity was determined by the correlations between the 
ACTS, BMQ general sub-scale, DMSE and HADS. Cronbach’s 
alpha assessed the internal consistency and identified items with 
poor alpha values. Multiple regression analyses using five predic-
tor variables was conducted with scores on the 22 item ACTS. 
The predictor variables were the HADS anxiety, HADS depres-
sion, DMSE, BMQ harm and BMQ overuse. The relationship 
between scores on the Morisky adherence scale and the ACTS 
were examined.
Results
Descriptive statistics
Of  the 878 questionnaires distributed, 23 were returned unde-
livered, 42 were returned unanswered. Of  the 855 active sample 
participants, 480 (56%) questionnaires were finally returned. Four 
hundred and eighty participants completed the 34-item ACTS. 
The sample size recommended for PCA is a minimum of  5, or 
10–15 subjects per item [25, 26]. The target sample size for the 
study was between 340 and 510, and was achieved.
The mean (SD, range) age of  respondents was 66.31 years (9.58, 
28-94); 308 respondents (68.6%) were male. The mean score on 
the 34-item ACTS was 99.07 (SD=12.86) scores ranged between 
50 and 140 and were normally distributed. Cronbach alpha for 
the ACTS was 0.78; which is generally accepted as indicating reli-
ability. Table 1 shows the frequency of  medicines prescribed. The 
mean number of  medicines prescribed was 4.8 (range 3-12).
Principle Component Analysis
Preliminary assessment of  the data was undertaken to determine 
its suitability for PCA. Two, four, five, six and seven factor rota-
tions were inspected; the logical and theoretically soundness of  
each rotation was considered. Strong consideration was given to 
a six and a four factor solution; the four factor solution was ac-
cepted based on the break in the screen plot (see Figure 1 & 2), 
and the component matrix (Table 2). The accumulative variance 
accounted by a four factor rotation explained 36.74% of  the vari-
ance.
The four factor solution was rotated using a direct oblique PCA 
method. The factor loadings on each component were examined. 
Items were deleted from the ACTS if  the factor loading was less 
than 0.33 [27]. Also, items loaded on to a second factor with a fac-
tor loading of  above 0.4 were also deleted. Following the deletion 
of  items confirmatory PCA was undertaken to confirm the 4 fac-
tor solution. Table 2 shows the remaining 22 items in the ACTS 
following the four factor rotation.
Cronbach alpha
Cronbach alpha was calculated for the 22 item ACTS (following 
PCA). A good level of  reliability for the 22 item ACTS was found 
(0.76). The overall internal consistency of  each scale (as indicated 
by Cronbach's alpha values) was not improved by the deletion of  
any scale items. Cronbach alpha for the four factors rotated using 
PCA are as follows: factor 1=0.78; factor 2=0.72; factor 3=0.73; 
factor 4=0.45.
Validity Testing
The regression analysis revealed that the independent variables 
accounted for 39.7% of  the variance in the ACTS (compared 
with 32.5% of  the variance before PCA was undertaken and 
poorly performing items were removed). All criterion variables, 
with the exception of  depression, were significant predictors of  
the ACTS. High scores on the ACTS were related to high scores 
on the HADS anxiety (beta=0.16, p<.01) BMQ over-prescribing 
(beta = 0.33, p<.01) and BMQ harm subscales (beta= .21, p<.01). 
Scores on the ACTS were not significantly related to HADS de-
pression scores (beta=0.09, sig = 0.16). Finally, high score on the 
ACTS were significantly related to low scores on DM self-efficacy 
(beta=-0.151, p<.01); therefore, high ACTS scores were related 
to lower levels of  self-efficacy. Overall scores on the ACTS were 
significantly correlated with non-adherence to medicines (r=364, 
p<.01).
Validity of  the ACTS subscales
Factor 1; The mean score was 21.29 (sd=4.91). The criterion 
measures accounted for 46% of  the variance in the concerns 
about multiple medicines and increasing numbers of  medicines 
subscale. Measures of  depression and perceptions of  harm were 
found to be significant predictors of  this subscale (depression 
beta=.228, p<.01; harm beta=.376, p<.01). The concerns about 
multiple medicines and increasing numbers of  medicines subscale 
was significantly correlated with non-adherence to medicines 
(r=.312, p<.01) (see Table 3).
Factor 2; The mean score on this subscale was 8.48 (sd=2.76). 
Figure 1. Scree plot for original pool of  items.
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The criterion measures accounted for 3.4% of  the variance in the 
anxiety over missed medicines subscale. Anxiety was a significant 
predictor of  this subscale (beta=.256, p<.01). The anxiety over 
missed medicines subscale was not a significant predictor of  non-
adherence (r=.074, p=.18).
Factor 3; The mean score was 22.35 (sd=4.59). The criterion 
measures accounted for 39.3% of  the variance in the desire to 
substitute medicines and reduce the number of  medicines pre-
scribed subscale. Measure of  depression and over-prescrib-
ing were significant predictors for this subscale (depression 
beta=.221, p<.01; over-prescribing beta=.234, p<.01). The desire 
to substitute medicines and reduce the number of  medicines pre-
scribed subscale was significantly correlated with non-adherence 
to medicines (r=.233, p<.01). 
Factor 4; The mean score was 12.02 (sd=2.79). The criterion 
measures accounted for 22.2% of  the variance in the perceptions 
related to organising and managing complex therapy subscale. 
The measure of  perceptions of  over prescribing was a significant 
predictor for this subscale (beta=.234, p<.01). The perceptions 
related to organising and managing complex therapy subscale was 
significantly correlated with non-adherence (r=.231, p<.01).
Discussion
The ACTS was developed to measure attitudes towards taking 
multiple medicines for the management of  T2D and CVD. The 
scale was originally developed from qualitative interviews and 
represents the difficulties people report facing when managing 
complex pharmacological therapies for T2D and CVD. Reliabil-
ity and validity techniques were then applied to the ACTS to en-
hance the psychometric properties of  this scale. Four key factors 
were identified through PCA: concerns about multiple medicines 
and increasing numbers of  medicines; anxiety over missed medi-
cines; desire to substitute medicines and reduce the number of  
Figure 2.  Scree plot following the deletion of  items: 22 item ACTS.
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Table 3. Beta values and significance levels of  the relationships between ACTS subscales and the criterion variables.
Beta Sig
1. Factor 1 HADS anxiety .109 .107
HADS depression .228 .002
DMSE (self-efficacy) -.049 .396
BMQ over prescribing .055 .423
BMQ harm .376 .000
2. Factor 2 HADS anxiety .256 .000
HADS depression -.017 .816
DMSE (self-efficacy) .042 .481
BMQ over prescribing .011 .848
BMQ harm -.008 .901
3. Factor 3 HADS anxiety .111 .13
HADS depression .211 .005
DMSE (self-efficacy) -.096 .089
BMQ over prescribing .325 .000
BMQ harm .058 .431
4. Factor 4 HADS anxiety .119 .113
HADS depression -.052 .492
DMSE (self-efficacy) -.063 .247
BMQ over prescribing .234 .002
BMQ harm .707 .48
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medicines prescribed; and perceptions related to organising and 
managing complex therapy. These factors were consistent with 
themes previously identified in qualitative investigations with peo-
ple managing complex medication regimens [12, 13].
The ACTS subscales, while representing the beliefs of  people 
diagnosed with T2D and CVD, were found to share properties 
with measures of  medication beliefs and psychological wellbeing. 
The BMQ general beliefs scale contains items related to a person 
general orientation towards medicines, and specifically asks about 
beliefs related to harm and over-prescribing [28]. The ACTS 
subscale on concerns about multiple medicines and increasing 
numbers of  medicines was only found to correlate with BMQ 
subscale related to perceptions of  medicines harm. Surprisingly, 
this subscale did not relate to the BMQ subscale on over prescrib-
ing. In addition increased concerns about multiple medicines and 
increasing numbers of  medicines were correlated with depressive 
thoughts as measured by the HADS. Similarly to the self-regula-
tion model and necessity-concern framework, we found emotion 
plays an important role in the management of  multiple medicines. 
The ACTS represents emotional representation of  medicine tak-
ing, as a subscale which focuses on feelings of  anxiety or worry 
when medicines are forgotten or accidentally missed was identi-
fied. Higher scores on this subscale were associated with anxious 
thoughts (as measured by the HADS anxiety scale).
Unlike other beliefs scales, the ACTS, by focusing on the medica-
tion perceptions of  a specific population, has identified unique 
characteristics such as the desires to reduce the number of  medi-
cines prescribed and substitute medicines with lifestyle interven-
tions. Further research could explore whether patients who hold 
these beliefs are more motivated to engage in life-style changes; 
this subscale was significantly correlated with depression. It is 
possible that those who want to reduce or substitute their medi-
cines may experience lower levels of  perceived control and ex-
perience higher levels of  depression. Other research has found a 
relationship between depression and non-adherence, and report-
ed that this relationship was mediated by perceived control [29]. 
However, these relationships need to be explored in more depth 
before conclusions can be drawn.
The large dataset drawing participants from an integrated primary 
and secondary care settings and the good questionnaire response 
rate are methodological strengths of  this research. Despite the 
benefits of  this research, limitations of  the ACTS should be ac-
knowledged. A difficulty with PCA is that the names given to the 
factors rotated are subjectively derived. If  a factor’s label does 
not reflect the attributes that link items together, the rotation 
of  a four-factor solution could be questioned. This issue could 
be resolved by undertaking confirmatory PCA on an alternative 
dataset to confirm the appropriateness of  a four-factor solution. 
A disadvantage can arise within PCA if  items share similar prop-
erties, but still remain fundamentally distinct from one another. 
In such cases, PCA may assign them to a single factor. However, 
it is widely accepted that the interpretation of  PCA uses both 
objective and subjective criteria. In this case, it is the judgment of  
the Investigators that these items share a common theme that is 
reflected by the title given to the factor.
The choice was made to extract questionnaire items from qualita-
tive interview findings, therefore, the scale items are statements 
made by people with T2D and CVD. In hindsight, further face 
validation of  the questionnaire items in a larger population of  
people managing T2D and CVD, may have refine the phrasing 
of  some questionnaire items. In addition, further work to ensure 
that scale items could be understood by people with lower levels 
of  literacy is required. Future research should develop the ACTS 
through methods such as cognitive interviewing and Rasch mod-
elling methods. These methods can be used to refine times, en-
hance validity and provide the ACTS with appropriate weights to 
the questionnaire items. The ability of  the ACTS to predict non-
adherence is shared with other measures. Further validation of  
this tool is required to demonstrate its distinctiveness from other 
scales especially the BMQ. There is some variation in the number 
of  items within each scale which may have implications for the 
way the ACTS is scored. Balancing the contribution of  each sub-
scale to the overall score of  the ACTS is important, and further 
investigation in to the weighting items is required.
The identification of  non-adherence in people with T2D has been 
identified as a priority [30]. Scores on the ACTS were correlated 
with non-adherence to medicines, and identified specific medicine 
taking beliefs held by people with T2D. This tool could be used to 
identify people experiencing difficulties managing multiple medi-
cines, and who are likely to be non-adherent to one of  more of  
their medicines. The clinical use of  the ACTS should be estab-
lished, we encourage the use of  the ACTS during consultations 
with patients prescribed multiple medicines for T2D and CVD.
References      
[1]. Fortin M, Soubhi H, Hudon C, Bayliss EA, van den Akker M (2007) Multi-
morbidity's many challenges. BMJ  334(7602): 1016-1017.
[2]. Booth GL, Kapral MK, Fung K, Tu JV (2006) Recent trends in cardiovascu-
lar complications among men and women with and without diabetes. Dia-
betes Care 29(1): 32-37.
[3]. Booth GL, Kapral MK, Fung K, Tu JV (2006) Relation between age and 
cardiovascular disease in men and women with diabetes compared with 
non-diabetic people: a population-based retrospective cohort study. Lancet 
368(9529): 29-36.
[4]. Kirsh SR, Aron DC (2011) Choosing targets for glycaemia, blood pressure 
and low-density lipoprotein cholesterol in elderly individuals with diabetes 
mellitus. Drugs Aging  28(12): 945-960.
[5]. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, et al. (2006) Ad-
ditive effects of glycaemia and blood pressure exposure on risk of complica-
tions in type 2 diabetes: a prospective observational study (UKPDS 75). 
Diabetologia 49(8): 1761-1769.
[6]. Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a 
multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 
358(6): 580-591.
[7]. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, et al. 
(2004) Primary prevention of cardiovascular disease with atorvastatin in type 
2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): mul-
ticentre randomised placebo-controlled trial. Lancet 364(9435): 685-696.
[8]. Mackey K, Parchman ML, Leykum LK, Lanham HJ, Noel PH, et al. (2012) 
Impact of the Chronic Care Model on medication adherence when patients 
perceive cost as a barrier. Prim Care Diabetes 6(2): 137-142.
[9]. Jenkins N, Hallowell N, Farmer AJ, Holman RR, Lawton J (2011) Par-
ticipants' experiences of intensifying insulin therapy during the Treating to 
Target in Type 2 Diabetes (4-T) trial: qualitative interview study. Diabet 
Med 28(5): 543-548.
[10]. Farmer A, Kinmonth AL, Sutton S (2006) Measuring beliefs about taking 
hypoglycaemic medication among people with Type 2 diabetes. Diabet Med 
23(3): 265-270.
[11]. Morrow AS, Haidet P, Skinner J, Naik AD (2008) Integrating diabetes self-
management with the health goals of older adults: a qualitative exploration. 
Patient Educ Couns 72(3): 418-423.
[12]. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, et al. (2002) 
Relationship between daily dose frequency and adherence to antihyperten-
sive pharmacotherapy: evidence from a meta-analysis. Clin Ther 24(2): 302-
316.
[13]. White AJ, Kellar I, Prevost AT, Kinmonth AL, Sutton S, et al. (2012) Adher-
ence to hypoglycaemic medication among people with type 2 diabetes in 
primary care. Prim Care Diabetes 6(1): 27-33.
Rebecca J Stack, et al., (2015) The Attitudes about Complex Therapy Scale (ACTS) in Type 2 Diabetes and Cardiovascular Disease: Development, Validity and Reliability. 
Int J Diabetol Vasc Dis Res, 3(9) 130-136 136
www.scidoc.org/ijdvr.php
[14]. Stack RJ, Bundy CE, Elliott R, New JP, Gibson M, et al. (2010) Intentional 
and unintentional non-adherence in community dwelling people with type 
2 diabetes: the effect of varying numbers of medicines. The British journal of 
Diabetes and Vascular Disease 10(3): 148-152. 
[15]. Stack RJ, Elliott RA, Noyce PR, Bundy C (2008) A qualitative exploration 
of multiple medicines beliefs in co-morbid diabetes and cardiovascular dis-
ease. Diabet Med 25(10): 1204-1210.
[16]. Anthony H, Valinsky L, Inbar Z, Gabriel C, Varda S (2012) Perceptions of 
hypertension treatment among patients with and without diabetes. BMC 
Fam Pract 13: 24.
[17]. Stack RJ, Bundy C, Elliott RA, New JP, Gibson JM, et al. (2011) Patient 
perceptions of treatment and illness when prescribed multiple medicines for 
co-morbid type 2 diabetes. Diabetes Metab Syndr Obes 4: 127-135.
[18]. Elliott RA, Ross-Degnan D, Adams AS, Safran DG, Soumerai SB (2007) 
Strategies for coping in a complex world: adherence behavior among older 
adults with chronic illness. J Gen Intern Med 22(6): 805-810.
[19]. Townsend A, Hunt K, Wyke S (2003) Managing multiple morbidity in mid-
life: a qualitative study of attitudes to drug use. BMJ 327(7419): 837.
[20]. Weinman J, Petrie KJ, Moss-Morris R, Horne R (1996) The Illness Percep-
tion Questionnaire: A new method for assessing the cognitive representation 
of illness. Psychology and Health 11(3): 431-446.
[21]. Horne R, Weinman J, Hawkins M (1999) The beliefs about medicines ques-
tionnaire: the development and evaluation of a new method for assessing the 
cognitive representation of medication. Psychology and Health 14(1): 1-24.
[22]. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. 
Acta Psychiatr Scand 67(6): 361-370.
[23]. Stanford Patient Education Research Centre. Diabetes Self-Efficacy Scale. 
2011. Ref Type: Online Source
[24]. Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive va-
lidity of a self-reported measure of medication adherence. Med Care 24(1): 
67-74.
[25]. Pett MA, Lackey NR, Sullivan JJ (2003) Making sense of factor analysis. The 
use of factor analysis for instrument development in health care research. 
Sage Publications.
[26]. Hatcher LA (1994) A step-by-step approach to using the SAS(R) system 
for factor analysis and structural equation modeling. SAS Institute, North 
Carolina, US .
[27]. Kline P (1994) An Easy Guide to Factor Analysis. Routledge, London.
[28]. Horne R, Weinman J (1999) Patients' beliefs about prescribed medicines 
and their role in adherence to treatment in chronic physical illness. J Psycho-
som Res 47(6): 555-567.
[29]. DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk fac-
tor for noncompliance with medical treatment: meta-analysis of the effects 
of anxiety and depression on patient adherence. Arch Intern Med 160(14): 
2101-2107.
[30]. National Institute for Health and Clinical Excellence (2009) Medicines ad-
herence: Involving patients in decisions about prescribed medicines and sup-
porting adherence. London. 
